NCT04214249
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04214249
Title BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Alabama at Birmingham Cancer Center Birmingham Alabama 35233 United States Details
UC Irvine Health/Chao Family Comprehensive Cancer Center Orange California 92868 United States Details
Yale University New Haven Connecticut 06520 United States Details
Mayo Clinic in Florida Jacksonville Florida 32224-9980 United States Details
Northwestern University Chicago Illinois 60611 United States Details
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon New Hampshire 03756 United States Details
Wake Forest University at Clemmons Clemmons North Carolina 27012 United States Details
Wake Forest Baptist Health - Wilkes Medical Center Wilkesboro North Carolina 28659 United States Details
Wake Forest University Health Sciences Winston-Salem North Carolina 27157 United States Details
Virginia Commonwealth University/Massey Cancer Center Richmond Virginia 23298 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field